Do antiosteoporotic drugs improve bone regeneration in vivo?

Eur J Trauma Emerg Surg. 2020 Apr;46(2):287-299. doi: 10.1007/s00068-019-01144-y. Epub 2019 Apr 26.

Abstract

Purpose: Treatment of complex fractures in the elderly is a challenge for operative reconstruction due to degraded bone structure. Early peri-operative bone anabolic treatment could improve new bone formation, avoid implant loosening and accelerate fracture healing.

Methods: To compare the osteoanabolic potential of different drugs after distraction osteogenesis, 168 female Sprague-Dawley rats underwent lengthening of the right femur using a monolateral external fixator. Animals were randomly divided into six groups: vehicle-injected group, PTH(1-34), raloxifen, strontium ranelate, alendronate and simvastatin. Histomorphometry, CT-scanning, DEXA- and biomechanical analysis were performed to evaluate new bone formation, callus volume, mineralisation and biomechanical strength. Expression of bone metabolic mediators and differentiation indicators of distracted and intact bone were examined by RT-PCR and western blot.

Results: Histological analysis showed significant increase of the bone mass after treatment with PTH(1-34), raloxifen and strontium ranelate (p = 0.02). Raloxifen increased bone mineral content (BMC) of the whole distracted femur significantly (p = 0.007). Callus volume was significantly larger in the PTH(1-34), raloxifen and simvastatin groups (p = 0.001) compared to control. Ultimate load of distracted new formed bone was increased in PTH(1-34) and raloxifen groups. It seems that PTH(1-34) and raloxifen have a stronger effect on bone where a repair response is activated. Strontium ranelate demonstrates similar effects to PTH regarding new bone formation but shows low values for mineralisation and biomechanical strength.

Conclusion: This study suggests that peri-operative treatment of complex and/or osteoporotic fractures with PTH(1-34) and raloxifen might be useful as a stimulator of bone formation and mineralisation to shorten the consolidation time in humans.

Keywords: Alendronate; Femur defect; Osteoporosis; Parathormone; Raloxifen; Simvastatin; Strontium ranelate.

MeSH terms

  • Absorptiometry, Photon
  • Alendronate / pharmacology
  • Alkaline Phosphatase / drug effects
  • Alkaline Phosphatase / metabolism
  • Animals
  • Biomechanical Phenomena / drug effects
  • Blotting, Western
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / pharmacology*
  • Bone Morphogenetic Protein 2 / drug effects
  • Bone Morphogenetic Protein 2 / genetics
  • Bone Regeneration / drug effects*
  • Bony Callus / diagnostic imaging
  • Bony Callus / metabolism
  • Bony Callus / pathology
  • Calcium-Regulating Hormones and Agents / pharmacology
  • Collagen Type I / drug effects
  • Collagen Type I / metabolism
  • Female
  • Femur / diagnostic imaging
  • Femur / drug effects*
  • Femur / pathology
  • Femur / surgery
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Interleukin-6 / genetics
  • Macrophage Colony-Stimulating Factor / drug effects
  • Macrophage Colony-Stimulating Factor / genetics
  • Osteocalcin / drug effects
  • Osteocalcin / genetics
  • Osteogenesis / drug effects*
  • Osteogenesis / genetics
  • Osteogenesis, Distraction
  • Parathyroid Hormone / pharmacology
  • RANK Ligand / drug effects
  • RANK Ligand / genetics
  • Raloxifene Hydrochloride / pharmacology
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction
  • Simvastatin / pharmacology
  • Thiophenes / pharmacology
  • Tomography, X-Ray Computed

Substances

  • Bmp2 protein, rat
  • Bone Density Conservation Agents
  • Bone Morphogenetic Protein 2
  • Calcium-Regulating Hormones and Agents
  • Collagen Type I
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Il6 protein, rat
  • Interleukin-6
  • Parathyroid Hormone
  • RANK Ligand
  • Thiophenes
  • strontium ranelate
  • Osteocalcin
  • Raloxifene Hydrochloride
  • Macrophage Colony-Stimulating Factor
  • Simvastatin
  • Alkaline Phosphatase
  • Alendronate